Related Experiment Video

Updated: May 31, 2026

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)
04:12

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA-TPA)

Published on: December 19, 2019

Rapamycin and mTORC1 inhibition in the mouse: skin cancer prevention

Mohammad Athar1, Levy Kopelovich

  • 1Department of Dermatology, Skin Diseases Research Center and UAB Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Cancer Prevention Research (Philadelphia, Pa.)
|July 8, 2011
PubMed

Insights

Rapamycin inhibits mTOR complex 1 in mouse skin, reducing tumor promotion and inflammation. This offers potential for preventing nonmelanoma skin cancer (NMSC) by targeting key molecular pathways.

Area of Science:

  • Dermatology
  • Oncology
  • Pharmacology

Background:

  • Rapamycin is known to reduce the risk of nonmelanoma skin cancer (NMSC) and Kaposi's sarcoma in organ transplant recipients.
  • The precise mechanisms underlying rapamycin's preventive effects against NMSC, beyond immunosuppression, require further elucidation.

Purpose of the Study:

  • To investigate the effects of rapamycin on mTOR complex 1 (mTORC1) signaling in murine epidermis.
  • To determine rapamycin's role in inhibiting tumor promotion and its associated anti-inflammatory effects in a skin cancer model.

Main Methods:

  • Utilized a murine model to study the impact of rapamycin on epidermal mTORC1.
  • Assessed tumor promotion mediated by tetradecanoyl phorbol-13 acetate (TPA) in the presence of rapamycin.
  • Evaluated the anti-inflammatory effects associated with rapamycin treatment.

Main Results:

  • Rapamycin effectively inhibits mTORC1 signaling within the murine epidermis.
  • Rapamycin demonstrated inhibition of TPA-mediated tumor promotion.
  • A significant anti-inflammatory effect was observed in conjunction with rapamycin's action.

Conclusions:

  • Rapamycin's inhibition of epidermal mTORC1 is a key mechanism for its anti-tumorigenic and anti-inflammatory effects in skin.
  • Understanding these pathways could lead to novel therapeutic strategies for NMSC prevention.
  • Future research should focus on identifying predictive biomarkers for rapamycin sensitivity and exploring combination therapies to enhance efficacy and minimize toxicity.

More Related Videos

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model12:37

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...